Corcept Therapeutics
CORT
223 hedge funds and large institutions have $1.55B invested in Corcept Therapeutics in 2020 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 73 increasing their positions, 83 reducing their positions, and 31 closing their positions.
25% more call options, than puts
Call options by funds: $25.1M | Put options by funds: $20.1M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
3% more capital invested
Capital invested by funds: $1.51B → $1.55B (+$44M)
0% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 31
0% less funds holding
Funds holding: 224 → 223 (-1)
1.06% less ownership
Funds ownership: 78.17% → 77.11% (-1.1%)
12% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 83
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$15.5M |
| 2 |
Renaissance Technologies
New York
|
+$10.9M |
| 3 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$10.3M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$8.77M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$12.9M |
| 2 |
Goldman Sachs
New York
|
-$7.71M |
| 3 |
Millennium Management
New York
|
-$6.97M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.1M |
| 5 |
AWS
AJ Wealth Strategies
New York
|
-$4.33M |
CORT Hedge Fund Activity: Q3 2020 in Review
223 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q3 2020, worth a combined $1.55B — up 2.9% from $1.51B a quarter earlier.
Fund positioning in CORT was balanced in Q3 2020: 31 funds opened new positions, 31 closed out, 73 added to existing stakes and 83 trimmed.
The largest buyer was Invesco, adding an estimated $15.5M. The largest seller was BlackRock, cutting an estimated $12.9M.
- 223 institutional investors held Corcept Therapeutics (CORT) as of Q3 2020, down from 224 in Q2 2020.
- Funds reported $1.55B of Corcept Therapeutics stock for Q3 2020, up 2.9% quarter-over-quarter.
- 31 funds opened new Corcept Therapeutics positions in Q3 2020 and 31 closed out, a net change of 0 holders.
- The largest Corcept Therapeutics buyer in Q3 2020 was Invesco, an estimated $15.5M added.
- The largest Corcept Therapeutics seller in Q3 2020 was BlackRock, an estimated $12.9M sold.
Based on aggregated 13F filings for Q3 2020.